Boehringer Ingelheim and Salipro enter drug discovery partnership
The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
The Pharma Letter1d
Salipro Biotech inks deal with Boehringer
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...
Contract Pharma1d
Boehringer Ingelheim Taps Salipro Biotech to Accelerate Pipeline Programs
Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...
Fierce Biotech1d
Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...